Literature DB >> 19499245

Impact of erythropoietin on the effects of irradiation under hypoxia.

Cristiana Lo Nigro1, Monica Maffi, Jean Louis Fischel, Martino Monteverde, Paolo Catarsi, Federica Tonissi, Laura Lattanzio, Michela Riba, Marie-Christine Etienne-Grimaldi, Patricia Formento, Gerard Milano, Marco Merlano.   

Abstract

PURPOSE: Head and neck squamous cell carcinoma (HNSCC) represents an ideal model for assessing the impact of anemia and tumor hypoxia on the response to radiotherapy (RT). Various treatment strategies aimed at increasing tumor oxygenation in HNSCC patients have been studied and these studies have been fueled by evidence that hypoxia and, unexpectedly, erythropoietin (EPO), adversely affect the radiosensitivity of cells. The purpose of the present study was to experimentally examine the relationship between hypoxia, EPO, its receptor EPOR, EGFR and their effects on the survival and radiosensitivity of HNSCC cells underwent hypoxia.
METHODS: We used Cal-166 head and neck cell line to investigate different cellular responses after RT given in oxic and hypoxic conditions, focusing on the role of EPO administration in cell proliferation and in regulating response to RT.
RESULTS: Our results show that EPO do not evoke a physiologic response on EPOR-bearing tumor cells as assessed by cellular growth and proliferation. In addition, we present some indications that EPO could activate opposite signals related to proliferation, DNA repair and apoptosis. Among them, EGFR and AKT phosphorylation may play a role in radioresistance.
CONCLUSIONS: We concluded that the expression of the EPOR in Cal-166 cells does not seem essential for their growth and that administration of EPO does not affect RT efficacy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19499245     DOI: 10.1007/s00432-009-0609-1

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  41 in total

1.  Breast cancer trial with erythropoietin terminated unexpectedly.

Authors:  Brian Leyland-Jones
Journal:  Lancet Oncol       Date:  2003-08       Impact factor: 41.316

2.  rHuEPO and treatment outcomes: the preclinical experience.

Authors:  Heinz Ludwig
Journal:  Oncologist       Date:  2004

3.  Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.

Authors:  Brian Leyland-Jones; Vladimir Semiglazov; Marek Pawlicki; Tadeusz Pienkowski; Sergei Tjulandin; George Manikhas; Antoly Makhson; Anton Roth; David Dodwell; Jose Baselga; Mikhail Biakhov; Konstantinas Valuckas; Edouard Voznyi; Xiangyang Liu; Els Vercammen
Journal:  J Clin Oncol       Date:  2005-08-08       Impact factor: 44.544

Review 4.  The impact of hemoglobin levels on treatment outcomes in patients with cancer.

Authors:  T J Littlewood
Journal:  Semin Oncol       Date:  2001-04       Impact factor: 4.929

5.  Induction of signalling in non-erythroid cells by pharmacological levels of erythropoietin.

Authors:  E A Dunlop; M J Percy; M P Boland; A P Maxwell; T R Lappin
Journal:  Neurodegener Dis       Date:  2006       Impact factor: 2.977

6.  The erythropoietin-receptor pathway modulates survival of cancer cells.

Authors:  Frank Pajonk; Antonia Weil; Alfred Sommer; Rafal Suwinski; Michael Henke
Journal:  Oncogene       Date:  2004-11-25       Impact factor: 9.867

Review 7.  Biology of erythropoietin.

Authors:  C Lacombe; P Mayeux
Journal:  Haematologica       Date:  1998-08       Impact factor: 9.941

8.  Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.

Authors:  Thomas E Witzig; Peter T Silberstein; Charles L Loprinzi; Jeff A Sloan; Paul J Novotny; James A Mailliard; Kendrith M Rowland; Steven R Alberts; James E Krook; Ralph Levitt; Roscoe F Morton
Journal:  J Clin Oncol       Date:  2004-09-27       Impact factor: 44.544

9.  Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression.

Authors:  Geza Acs; Paul J Zhang; Cindy M McGrath; Peter Acs; John McBroom; Ahmed Mohyeldin; Suzhen Liu; Huasheng Lu; Ajay Verma
Journal:  Am J Pathol       Date:  2003-06       Impact factor: 4.307

10.  Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells.

Authors:  A M Sinclair; N Rogers; L Busse; I Archibeque; W Brown; P D Kassner; J E V Watson; G E Arnold; K C Q Nguyen; S Powers; S Elliott
Journal:  Br J Cancer       Date:  2008-03-18       Impact factor: 7.640

View more
  2 in total

1.  Recombinant human erythropoietin promotes the acquisition of a malignant phenotype in head and neck squamous cell carcinoma cell lines in vitro.

Authors:  Eric Abhold; Elham Rahimy; Jessica Wang-Rodriguez; Katherine J Blair; Michael A Yu; Kevin T Brumund; Robert A Weisman; Weg M Ongkeko
Journal:  BMC Res Notes       Date:  2011-12-21

Review 2.  Current relevance of hypoxia in head and neck cancer.

Authors:  Marius G Bredell; Jutta Ernst; Ilhem El-Kochairi; Yuliya Dahlem; Kristian Ikenberg; Desiree M Schumann
Journal:  Oncotarget       Date:  2016-08-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.